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OR I G INA L ART I C L E
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Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a segmental progeroid syndrome with multiple features suggestive of
premature accelerated aging. Accumulation of progerin is thought to underlie the pathophysiology of HGPS. However, despite
ubiquitous expression of lamin A in all differentiated cells, the HGPS mutation results in organ-speciﬁc defects. For example,
bone and skin are strongly affected by HGPS, while the brain appears to be unaffected. There are no deﬁnite explanations as to
the variable sensitivity to progeria disease among different organs. In addition, low levels of progerin have also been found in
several tissues from normal individuals, but it is not clear if low levels of progerin contribute to the aging of the brain. In an
attempt to clarify the origin of this phenomenon, we have developed an inducible transgenic mouse model with expression of
the most common HGPS mutation in brain, skin, bone and heart to investigate how the mutation affects these organs.
Ultrastructural analysis of neuronal nuclei after 70 weeks of expression of the LMNA c.1824C>T mutation showed severe
distortion with multiple lobulations and irregular extensions. Despite severe distortions in the nuclei of hippocampal neurons
of HGPS animals, there were only negligible changes in gene expression after 63 weeks of transgenic expression. Behavioral
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analysis and neurogenesis assays, following long-term expression of the HGPS mutation, did not reveal signiﬁcant pathology.
Our results suggest that certain tissues are protected from functional deleterious effects of progerin.
Introduction
Hutchinson–Gilford progeria syndrome (HGPS, progeria) is a very
rare genetic disease characterized bymultiple features of acceler-
ated premature aging in children (1). The affected individuals dis-
play no signs of disease at birth, but within their ﬁrst few years of
life, they gradually develop an appearance often referred to as
aged-like. HGPS affects diverse body systems including skeleton,
body fat, skin, hair and the cardiovascular system. On average,
death occurs at the age of 13, with at least 90% of HGPS subjects
dying from progressive atherosclerosis of the coronary and cere-
brovascular arteries (2).
HGPSwas ﬁrst described by JonathanHutchinson and then by
Hastings Gilford in the late 19th century, but it was not until 2003
that the genetic basis of HGPS was discovered (3,4). The under-
lying genetic defect for 90% of HGPS patients was found to be a
de novo heterozygous point mutation in exon 11 of the LMNA
gene (c.1824C>T, p.G608G). Although this mutation does not re-
sult in any changes in the amino acid sequence, it causes aber-
rant mRNA splicing and generates a truncated and partially
processed pre-lamin A protein named progerin. Unlike mature
lamin A, progerin lacks 50 amino acids, which include the intern-
al ZMPSTE24 cleavage site, and so remains permanently farnesy-
lated and carboxymethylated. Due to this structural change,
progerin remains attached to the nuclear membrane, conse-
quently causing a disruption in the integrity of the nuclear lam-
ina. Indeed, HGPS patient cells have a number of abnormalities in
nuclear structure and function. Using indirect immunoﬂuores-
cence labeling with antibodies directed against lamins A and C,
ﬁbroblasts from individuals with HGPS were characterized by
the presence of dysmorphic nuclei with altered size and shape, lo-
bules, wrinkles, herniations of the nuclear envelope, thickening of
the nuclear lamina, loss of peripheral heterochromatin and clus-
tering of nuclear pores (4,5). These features worsen with passages
in cell culture and are correlatedwith an apparent intranuclearac-
cumulation of progerin (5). Progerin has also been found to impair
the cell cycle by interfering with the disassembly and reassembly
of the nucleus during theMphase and after the G1 phase, respect-
ively (6). For this reason, accumulation of progerin is thought to
play a major role in the pathophysiology of HGPS.
Progerin has also been found to interfere with cellular func-
tions of normally aging cells. Cells from HGPS patients and nor-
mally aged individuals share several common nuclear defects,
and cells from unaffected individuals also express progerin (7).
Additionally, a small amount of progerin protein was detected
in protein extracts derived from elderly individuals but was ab-
sent in samples from the young (8). Rodriguez et al. quantiﬁed
the levels of progerin transcripts using real-time quantitative re-
verse transcriptase polymerase chain reaction (RT-PCR) and
showed that the progerin transcript is present in unaffected eld-
erly individuals, although at avery low level comparedwithHGPS
patients, and this level increased with in vitro aging, similar to
HGPS cells (9). Recently, Olive and others reported that progerin
is present in the coronary arteries of non-HGPS aging individuals
and signiﬁcantly increases with advancing age (10). On thewhole,
accumulation of progerin, which is formed sparsely over time as a
result of the aging process, appears to be partially responsible for
the cellular senescence and genomic instability observed in aging
cells.
Despite the presence of multiple premature aging symptoms,
not all aging processes are advanced in HGPS children. For
example, progeria patients have no defects in their mental and
intellectual abilities, which suggests that the brain may be pro-
tected from, and/or insensitive to, and/or unaffected by, the ex-
pression of the progeria mutation. However, there are, to our
knowledge, no published studies that have investigated the neur-
onal accumulation of progerin in HGPS. In order to verify these
hypotheses, this study presents an inducible transgenic mouse
model that speciﬁcally expresses the most common LMNA
c.1824C>T HGPS mutation in neurons as well as in cells of bone,
skin and heart. The results from this study demonstrated that
long-term expression of the common HGPS mutation did not
result in any apparent neuropathological defects despite severe
nuclear distortions including nuclear blebbing and invaginations
of the hippocampal neurons. These intriguing results suggest
that post-mitotic cells are less sensitive to induced changes in
the nuclear lamina and that severe nuclear distortions do not
necessarily induce changes in gene expression or functional
changes in hippocampal activity.
Results
Correctly targeted and localized transgenic lamin
A/progerin in neurons and cells of the skin, bone and
heart
The transgenic expression was evaluated using immunoﬂuores-
cence and immunohistochemistry in the brain, skin and bone
(Fig. 1). The hippocampal region of the brain from 90-week
HGPS animals was analyzed for the expression pattern of trans-
genic lamin A/progerin in combination with mouse lamin A/C
(Fig. 1A–F). It was clear that the transgenic lamin A/progerin
was properly targeted to its correct location in the nucleus, that
is, the nuclear envelope, and formed a ‘ring’ structure around
the 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclear DNA
(Fig. 1A andC). Furthermore, transgenic laminA/progerin expres-
sion substantially overlapped the mouse lamin A/C expression
(Fig. 1B and C). Speciﬁc expression of the transgenic lamin A/pro-
gerin was also conﬁrmed by its absence in thewild-type animals
(Fig. 1D). The skin from 20-week HGPS animals was double-
labeled for the transgenic lamin A/progerin and keratin-5
(Fig. 1M–O); keratin-5 was labeled only for structural guidance
(Fig. 1N). The transgenic lamin A/progerin was observed in the
keratinocytes of the bulb of the hair follicle and scattered in the
dermal and hypodermal layers of the skin (Fig. 1M and O). Immu-
nohistochemical labeling of the transgenic lamin A/progerin in
the 20- and 90-week HGPS femur (Supplementary Material,
Fig. S1) showed that only 8.1% of HGPS osteocytes expressed
the transgene at 20 weeks, and this expression decreased to a
negligible level by 90 weeks of age (P = 0.048; Fig. 1T), suggesting
that the vast majority of cells in the bone tissue did not express
the transgene. In addition, there were also a few osteoblasts that
showed transgenic expression; however, the amount of cells was
very low and therefore not quantiﬁed. To be able to compare re-
sults to our previously characterized HGPSmodel using a different
transactivator, but with a severe bone phenotype (11), we counted
femoral osteocytes in 3-week Tetop-LAG608G+; Sp7-tTA+, F1-line
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VF1-07 and wild-type littermates. Our results showed that the
majority of osteocytes (92%) expressed the transgene when
using the Sp7-tTA-transactivator.
Expression of the LMNA c.1824C>T mutation in mice
Human lamin A and progerin transcripts were expressed in skin,
bone, brain and heart tissues of the HGPS animals (Tetop-LAG608G+;
NSE-tTA+) but were absent in wild-type animals (Tetop-LAG608G−;
NSE-tTA−) (Fig. 2A). There were also low levels of transgenic
expression in the brain and heart tissues of the single-transgenic
animals (Tetop-LAG608G+; NSE-tTA−) (Fig. 2A). In order to further
examine the expression level of the transgene in different regions
of thebrain,we focusedon threebrain regions, hippocampus, cortex
and cerebellum. The level of transgenic lamin A and progerin was
measured by quantitative RT-PCR (qRT-PCR) using primers speciﬁc
for human lamin A and progerin that do not cross-react with
mouse lamin A (Fig. 2B–D). The levels of both human lamin A and
progerindifferedbetweenthe three regions, ofwhich thecerebellum
had the lowest expression compared with the hippocampus or
the cortex, relative to β-actin (for lamin A: P = 0.0004 compared
with hippocampus, P = 0.0009 compared with cortex; for progerin:
P= 0.003 comparedwithhippocampus, P=0.021 comparedwith cor-
tex). However, the levels of human laminA and progerin expression
Figure 1. Expression pattern of the transgenic lamin A/progerin in brain, skin and bone and subsequent histopathological analyses. (A–F) Immunoﬂuorescent labeling of
90-week CA1 hippocampal brain regions from HGPS and wild-type animals. (G–L) Hematoxylin and eosin staining showed no noticeable pathology in various regions of
the brain in 90-week HGPS animals compared with wild-type animals. Representative images from hippocampus (CA3 region), frontal cortex and cerebellum. (M–O)
Immunoﬂuorescent labeling of 20-week skin showed that transgenic lamin A/progerin expression was observed in keratinocytes of the proximal part of the bulb of
the hair follicle, scattered ﬁbroblast-like cells in the dermis and cells of the hypodermis. (P–S) Skin tissues stained with hematoxylin and eosin showed that the
hypodermal layer (green bars), which is used to store subcutaneous fat, was lost in the 90-week HGPS animals. (T) Percentage of osteocytes that expressed the
transgenic lamin A/progerin in femur from 20- and 90-week-old HGPS animals. (U) Hematoxylin and eosin staining of the femur from 90-week-old HGPS animals with
osteocytes in most lacunae (arrowhead) and a healthy bone marrow. Values represent mean ± SEM (*P < 0.05).
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in the hippocampus and cortex were not signiﬁcantly different
(Fig. 2B–C). The ratio between the progerin and human lamin A
also displayed a similar pattern; the cerebellum had the lowest
level of progerin relative to human laminA,while the hippocampus
and cortex had higher, but similar, expression levels comparedwith
cerebellum (P= 0.003 compared with hippocampus, P= 0.0001 com-
pared with cortex; Fig. 2D).
The human lamin A and progerin proteins were detected in
the brain, bone and skin of the HGPS animals (Fig. 2E and data
not shown). The level of the transgenic overexpression of lamin
A in the 20-weekHGPS animals was quantiﬁed using an antibody
that targets both mouse and human lamin A (Fig. 2F). It showed
that in the brain, there was an increase of 3.15 over the level of
lamin A in the HGPS animals compared with wild-type animals
(P = 0.01), while there was only an increase of 0.39 and 0.22 in
the bone and skin, respectively (Fig. 2F). There were also low le-
vels of transgenic protein expression in brain tissue of the single
transgenic animal (Fig. 2E). This leaky expression corresponded
to 11% of the transgenic protein expression in the brain when
quantiﬁed by densitometry.
Lower bodyweight and shorter bone length in HGPSmice
HGPS animals expressed the LMNA c.1824C>T mutation from
embryonic day 12.5 until postnatal week 90, the maximum age
analyzed. Animals were born at the expected Mendelian fre-
quency, and therewas no signiﬁcant effect on life span compared
with wild-type littermates (P = 0.42, animals were allowed to age
until postnatal week 95). No abnormal behavior or obvious
external phenotype was observed, except for the slightly smaller
size of the HGPS animals. The body weights of the HGPS animals
were signiﬁcantly lower than those of wild-type animals at both
20 and 90 weeks of age (P = 0.004 for 20 weeks; P = 0.001 for 90
weeks; Fig. 2G). Furthermore, while body weights of the wild-
type animals increased signiﬁcantly with age (P = 0.0001), the
HGPS animals did not signiﬁcantly gain weight as they aged
(Fig. 2G).
Bone length andwidthweremeasured at 20weeks (Fig. 2H–K),
and the results showed that the HGPS animals had signiﬁcantly
shorter femurs and tibias compared with those of wild-type ani-
mals (P = 0.011 and P = 0.007, respectively; Fig. 2H and J). However,
there was no difference in femur and tibia width between the
HGPS and wild-type animals (Fig. 2I and K).
Loss of subcutaneous fat in HGPS mice
Despite the presence of multiple premature aging symptoms in
multiple organs of HGPS patients (for example, bone and skin),
other organs, such as liver, kidney, lung, brain, gastrointestinal
tract and bone marrow, appeared unaffected (1,2). In this study,
samples from brain, skin, bone and heart tissue were stained
with hematoxylin and eosin (H&E) for histopathological analysis
(Fig. 1). In spite of long-term expression of the LMNA c.1824C>T
mutation, 90-week HGPS animals did not exhibit any neuropatho-
logical changes compared with wild-type animals (Fig. 1G–L). To
rule out the possibility of apoptosis, which was previously
reported in HGPS, 90-week HGPS and wild-type brain tissues
were labeled for cleaved caspase-3. There were no indications of
Figure 1. Continued
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apoptosis (Supplementary Material, Fig. S2A and B). Immunohis-
tochemistry with an antibody for the glial ﬁbrillary acidic protein
(GFAP) didnot reveal anysigniﬁcant differences between theHGPS
and wild-type brain, with no indication of astrocyte activation in
the hippocampus or frontal cortex in 20- or 90-weekHGPS animals
(Supplementary Material, Fig. S3). Interestingly, there was a con-
siderable loss of the fat layer in the skin of 90-week HGPS animals
(Fig. 1S) compared with wild-type animals (green bar, Fig. 1R),
which may partly explain the lower body weight of HGPS animals
compared with wild-type animals (Fig. 2G). Nevertheless, there
Figure 2. Transgenic lamin A/progerin expression in mouse. (A) RT-PCR of skin, bone, brain and heart tissues from HGPS, single transgenic and wild-type mice using a
human lamin A and progerin-speciﬁc assay. Presence or absence of the transgene is indicated with + or –, respectively. (B–D) Relative transcript level of human lamin A
and progerin in three different regions of the brain: hippocampus, cortex and cerebellum. (E) Western blot analysis of protein extracts from mouse brain tissue using a
transgene-speciﬁc lamin antibody (anti-human lamin A/C, clone JoL2). Protein extracts from a HGPS patient were loaded as a positive control (PC). (F) Quantiﬁcation of
relative protein levels using densitometry. (G) Body weights of the HGPS and wild-type animals. (H–K) Bone length and width in HGPS compared with wild-type animals.
NTC, no template control. Values represent mean ± SEM (*P < 0.05, **P < 0.01–0.001, ***P < 0.001).
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was no apparent difference in the skin of 20-week animals (Fig. 1P
and Q). Twenty or 90 weeks of LMNA c.1824C>T mutation expres-
sion did not cause anymajor pathological changes in bone (Fig. 1U
and Supplementary Material, Fig. S1A and B). Most lacunae were
ﬁlled with osteocytes (arrowheads) and the bone marrow ap-
peared unaffected (Fig. 1U and Supplementary Material, Fig. S1A
and B). Emptyosteocyte lacunaewere counted in femoral sections
from HGPS and wild-type animals, but there were no signiﬁcant
differences. There was a slight increase in empty osteocyte lacu-
nae in HGPS animals with increased age, 3.49% at 20 weeks com-
pared with 6.06% empty osteocyte lacunae at 90 weeks. A similar
increase was seen in the sections from femur fromwild-type ani-
mals (3.32% at 20 weeks comparedwith 7.01% empty osteocyte la-
cunae at 90 weeks). Furthermore, animals were examined for the
presence of callus formation in the rib cage because this was pre-
viously associated with HGPS (11), but neither HGPS nor wild-type
animals had any calluses between 20 and 70weeks of age (Supple-
mentary Material, Fig. S1C–F). H&E and Masson’s trichrome stain-
ing of the heart tissue demonstrated no obvious defects in the
heart after 20 or 74weeks of LMNA c.1824C>Tmutation expression
(SupplementaryMaterial, Fig. S4). Furthermore, heart tissues from
74-week HGPS and wild-type animals showed no signs of apop-
tosis (Supplementary Material, Fig. S2C and D).
Progerin accumulates in the neuronal cells of the
hippocampus and frontal cortex with aging
One feature identiﬁed in HGPS that is believed to contribute
to disease progression is the accumulation of progerin during
disease progression (5,10). To investigate whether transgenic
lamin A and progerin proteins accumulate in different types of
tissue, immunoﬂuorescence was performed on the brain and
heart using a transgenic lamin A/progerin or progerin antibody,
and the number of positive cells was quantiﬁed (Fig. 3). The
number of cells expressing transgenic lamin A/progerin and
progerin was counted in the frontal cortex and the CA1 region
of the hippocampus in 20- and 90-week-old HGPS animals. Be-
cause very few cells expressed the transgene in the cerebellum
(Fig. 3C, F, J and M), the quantiﬁcation was performed only on
the CA1 region of the hippocampus and the frontal cortex. The la-
beling proﬁle of both transgenic lamin A/progerin- and progerin-
positive cells consisted of a nuclear rim (red) ﬁlled with DAPI
nuclear staining (blue) (Fig. 3). The number of neurons expressing
the transgenic lamin A/progerin in the CA1 region of the hippo-
campus was signiﬁcantly higher than in the frontal cortex
(P < 0.0001), but there was no difference between age groups
(Fig. 3G). There was a signiﬁcant increase in progerin-expressing
cells in 90-week animals, both in the CA1 region of the hippocam-
pus (P = 6.02 × 10−5) and in the frontal cortex (P = 0.004), compared
with 20-week-old animals (Fig. 3N). This increase in expression
was also visibly evident in the immunoﬂuorescence images
(Fig. 3H–M), especially in the CA1 region of the hippocampus
(Fig. 3H and K). Furthermore, consistent with the quantiﬁcation
of transgenic lamin A/progerin expression, the number of cells
expressing progerin in the CA1 region of the hippocampus was
signiﬁcantly higher than that of frontal cortex (P < 0.0001; Fig. 3N).
Both transgenic lamin A/progerin and progerin proteins were
detected in the cardiomyocytes of the heart tissue (both atrium
and ventricle regions) from 20- and 74-week-old HGPS animals
(Fig. 3O–R andU–X, respectively).When the number of transgenic
lamin A/progerin-positive cardiomyocytes was quantiﬁed, the
number of positive cells signiﬁcantly increased with age in both
regions of the heart, ventricle and atrium (P = 0.0008 for ventri-
cles, P = 0.030 for atria; Fig. 3S). There was a regional difference
in the number of cardiomyocytes expressing transgenic lamin
A/progerin, inwhich the level was higher in the atrium compared
with the ventricle (P = 0.009; Fig. 3S). However, there were no sig-
niﬁcant differences in the number of cells expressing progerin
between 20- and 74-week animals, nor between ventricle and
atrium regions of the heart (Fig. 3T).
Severe neuronal nuclear distortions were observed in the
hippocampus at the ultrastructural level
From the immunoﬂuorescence analyses, it was evident that the
transgenic human lamin A/progerin- and progerin-positive cells
in HGPS brain had abnormal nuclear morphology, with many
folds and blebs (Fig. 3A–F and H–M). In order to obtain higher
resolution images of neuronal nuclei, the CA1 region of the
hippocampus from 70-week HGPS and wild-type animals were
analyzed using transmission electron microscopy (Fig. 4).
Femur and white adipose tissue from the same group of animals
were also analyzed (Fig. 4). The hippocampal nuclei of HGPS ani-
mals were severely distorted, with multiple lobulations and ir-
regular extensions, which resulted in deep invaginations of the
nuclear envelope (Fig. 4B, D, K and L) compared with the normal
round nuclei of the wild-type animal (Fig. 4A and C). On average,
130 hippocampal neuronswere counted for each animal to quan-
tify the number of cells with abnormal nuclei. Notably, 95.5% of
hippocampal neurons of HGPS animals had either irregular
shape or severe invaginations that resulted in a fragmented ap-
pearance, which was signiﬁcantly higher than that of the wild-
type hippocampus (Fig. 4M). It has been shown that in HGPS
skin ﬁbroblasts, peripheral heterochromatin that normally lies
adjacent to the nuclear envelope is lost (5,12). Therefore, it was
important to search for this loss in the hippocampal neurons of
the HGPS animals. However, there was no apparent loss of per-
ipheral heterochromatin (arrows) in HGPS hippocampal neurons
compared with wild-type (Fig. 4E and F).
Ultrastructural changes in white adipocytes of HGPS
animals
Fifty osteoblasts, osteocytes and adipocytes from each animal
were analyzed for the presence of folds and/or blebs of the nu-
cleus, and the number of cells with these abnormalities was
quantiﬁed. There were no apparent differences in nuclear struc-
ture in osteoblasts or in osteocytes of HGPS animals compared
with wild-type animals (Fig. 4G–J). However, in 46% of adipocytes
from HGPS animals, there were noticeable folds and irregularity
in the nucleus compared with the relatively smooth wild-type
adipocyte nucleus (Fig. 4N–P).
No evidence of inclusions in the brain fromHGPS animals
It has been well documented that expression of mutant proteins
in post-mitotic neurons is often accompanied by deposition of
the aberrant proteins in ubiquitin-positive inclusion bodies (13).
Therefore, we explored whether the forced overexpression of
human lamin A and progerin in neurons of HGPS mice resulted
in the formation of ubiquitin inclusions. However, detailed ana-
lysis of the cortex and hippocampus in 90-week HGPS animals
did not reveal evidence of such structures in brain sections of
these mice (Supplementary Material, Fig. S5). We also analyzed
the brain for protein aggregates associated with Alzheimer’s dis-
ease, but foundno evidence for aberrant Tau in the brain sections
of HGPS animals (Supplementary Material, Fig. S6).
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Expression of abnormal proteins can also result in impair-
ment of the ubiquitin/proteasome system (14,15), which is the
primary intracellular proteolytic system that eliminates mis-
folded proteins (16). Moreover, it has been previously reported
that progerin can inhibit the catalytic activity of the proteasome
(17). To explore whether progerin causes functional impairment
of ubiquitin-dependent proteasomal degradation, we transiently
expressed wild-type lamin A or progerin, or a minigene that
expresses both lamin A and progerin, in a cell line that stably
expresses a green ﬂuorescent protein (GFP)-based reporter sub-
strate of the ubiquitin/proteasome system (Supplementary Ma-
terial, Fig. S7). Expression of the lamin A and/or progerin
variants did not cause accumulation of the reporter substrate of
the ubiquitin/proteasome system, suggesting that the system
Figure 3. Quantiﬁcation of the transgenic lamin A/progerin and progerin expression in the brain and heart. (A–F) Immunoﬂuorescent labeling of transgenic lamin
A/progerin in three different regions of the brain, including the CA1 region of hippocampus, frontal cortex and the Purkinje cell layer of the cerebellum, of the HGPS
animals. For both age groups, almost all cells were positive for the transgenic lamin A/progerin in the hippocampus, while in the cerebellum, there were very few
positive cells. (G) Quantiﬁcation of transgene-positive cells in the CA1 region of the hippocampus and the frontal cortex. (H–M) Immunoﬂuorescent labeling of
progerin in three different regions of the brain of HGPS animals. (N) Quantiﬁcation of progerin-positive cells in the CA1 region of the hippocampus and the frontal
cortex. (O–R) Immunoﬂuorescent labeling of transgenic lamin A/progerin in the heart from HGPS animals at 20 or 74 weeks of age. (S and T) Quantiﬁcation of cells
expressing transgenic lamin A/progerin or progerin. (U–X) Immunoﬂuorescent labeling of progerin in the ventricles and atria from the HGPS animals. Images of
immunoﬂuorescent staining were merged with DAPI. Values represent mean ± SEM (*P < 0.05, **P < 0.01–0.001, ***P < 0.001).
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remains sufﬁciently able to facilitate degradation of ubiquitin-
dependent substrates, regardless of its expression of progerin.
Accordingly, treatment with a small compound proteasome in-
hibitor resulted in accumulation of the GFP substrate in proger-
in-expressing cells, underscoring that the system is operative
even under conditions of overexpressed progerin.
Lamin B1 and miRNA expression in the brain
Recent studies have suggested that a decrease in lamin B1 levels
could serve as a marker for senescence (18–20). However, it has
been shown that overexpression of LMNB1 results in abnormal
nuclear morphology such as extensive folding, blebbing and
lobulation in the nuclear envelope of neuronal cell lines (21). In
this study, analysis of lamin B1 expression in different regions
of the brain in wild-type animals showed that the level of
Lmnb1 transcript decreased signiﬁcantly in an age-dependent
manner, in which the level was lowest at 126 weeks compared
with 3 and 87 weeks in all regions of the brain (P = 1.45 × 10−5 for
hippocampus, P = 0.0007 for cortex and P = 5 × 10−5 for cerebellum;
Fig. 5A). However, there was no difference between 3 and 87
weeks (Fig. 5A). Prior studies have shown that miR-23a targets
the LMNB1 gene and regulates lamin B1 expression (20,21). For
this reason, miR-23a expression in various regions of the wild-
type brain was analyzed at 3, 87 and 126 weeks of age (Fig. 5B).
Relative expression levels of miR-23a showed an increasing
Figure 4. Electronmicroscopic analyses of nuclei of various cell types from 70-week HGPS and wild-type animals. While thewild-type hippocampus nuclei from the CA1
region consistently had a smooth round shape (A andC), theHGPS hippocampal nuclei of the CA1 regionhad avery irregular shape (B andK) and presentedwith extensive
folding, blebbing and lobulation of the nuclear envelope, which was so severe that the nuclei looked fragmented (D and L). The images from the nuclear membranes
(arrowheads; E and F) of the hippocampal neurons in the wild-type (E) and HGPS (F) animals showed no apparent loss of heterochromatin (arrows). (G–J) There were
no signiﬁcant differences in the nuclear structure of osteoblasts or osteocytes. (M) Quantiﬁcation of abnormal nuclei in the hippocampus showed that 95.5% of
hippocampal neurons had abnormal nuclei, compared with 11% in wild-type animals. (N and O) Nuclei of adipocytes from HGPS animals showed moderate folding
and irregularity in nuclear morphology compared with wild-type animals. (P) Quantiﬁcation of the percentage of adipocytes with abnormal nuclei morphology.
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trend with age. Nevertheless, there was a signiﬁcant increase in
the level of miR-23a in the cortex at 87 weeks (P = 0.002), but this
level decreased again by 126 weeks (P = 0.0005), suggesting that
there may be regulators other than miR-23a that may govern
the expression of lamin B1. Relative Lmnb1 transcript expression
was alsomeasured in the brain tissue of 20-week HGPS andwild-
type animals. However, there were no signiﬁcant changes in the
level of Lmnb1 transcript in all regions of the brain of HGPS
animals compared with wild-type animals (Fig. 5C).
Recent studies have suggested that the lack of progeroid
phenotype in neuronal cells is due to down-regulation of lamin
A by a neural-speciﬁc microRNA, miR-9 (22,23). In this study,
the relative levels of lamin A and C proteins in the wild-type
brain, liver, kidney and bone tissues were analyzed by western
blot (Fig. 5D). The results showed that the lamin A and C proteins
were expressed at different levels in all investigated tissues. In
brain, the lamin A to C ratio was 0.65 (SD = 0.04); in kidney, 1.25
(SD = 0.20); in liver, 0.82 (SD = 0.13) and in bone, 3.47 (SD = 1.18).
To further understand the relative expression of lamin A and
B1 in the brain, relative levels of mouse lamin A and B1 tran-
scripts were quantiﬁed in different regions of the brain in wild-
type animals (Fig. 5E). In agreement with a prior study (22),
lamin B1 was more highly expressed in all regions of the brain
compared with lamin A (P < 0.0001 for all regions; Fig. 5E). Fur-
thermore, the cerebellum had the highest level of expression
for both lamin A and B1 comparedwith hippocampus and cortex
(P = 0.0007, P = 0.015, respectively; Fig. 5E).
The database of predicted and published microRNAs (miR-
Walk) suggested that in addition to miR-9, miR-124a and miR-
129 regulate the expression of lamin A. To determine whether
expression of the HGPS mutation results in changes in the
expression of lamin B1 or miRNAs that target lamin A, the levels
of lamin B1, miR-9, miR-124a and miR-129 were measured in 20-
week HGPS and wild-type animals (Fig. 5F–H). However, there
were no obvious changes in the levels of lamin B1 transcript or
in anymiRNAs upon transgenic expression of theHGPSmutation
(Fig. 5C and F–H).
Negligible global changes in gene expression in the
hippocampus
A number of studies have identiﬁed changes in gene expression
in cells fromHGPS patients and in tissues from animal models of
HGPS (24,25). To investigate whether the severe nuclear distor-
tions seen in 95.5% of the hippocampal neurons in HGPS animals
(Fig. 4B, D, K and L) resulted in changes in gene expression, global
genome transcript analysis was performed using Affymetrix
exon arrays with RNA extracted from the hippocampus of 63-
week-old HGPS and wild-type animals. Surprisingly, despite se-
vere distortions in the nuclei of hippocampal neurons of HGPS
animals (Fig. 4D, K and L), there were only negligible changes in
global gene expression. Only ﬁve genes, out of the 16 572 RefSeq
genes from the main meta-probe list, showed a statistically
signiﬁcant 2-fold change (Supplementary Material, Table S1).
Figure 5. Gene expression andmiRNA analyses of different regions of the brain in HGPS andwild-type animals. (A and B) Graphs showing the relative expression of lamin
B1 transcript (A) and miR-23a (B) in various regions of the brain from wild-type animals at 3, 83 and 126 weeks of age. (C) Lamin B1 transcript levels in HGPS animals
compared with wild-type animals. (D) Western blot showing the expression of mouse lamin A and C in brain, liver, kidney and tail-bone tissues from adult wild-type
animals. The sc-6215 antibody was used to detect the lamin A and C proteins. (E) Relative expression level of mouse lamin A and B1 transcripts in various regions of
the brain in 20-week-old wild-type animals. (F–H) Relative expression of miR-9 (F), miR-124a (G) and miR-129 (H) in various regions of the brain of 20-week HGPS and
wild-type animals. (I) Principal component analysis of the top 1000 genes with the highest average expression levels revealed very small changes in gene expression
in the hippocampi of HGPS animals (red) compared with wild-type (blue). Values represent mean ± SEM (*P < 0.05, **P < 0.01–0.001, ***P < 0.001).
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Principal component analysis (PCA) of samples grouped by geno-
type, using the Partek Genomic Suite software, did not result in
any speciﬁc clustering, again indicating that nomajor differences
in hippocampal gene expression between wild-type and HGPS
animals (Fig. 5I).
Behavioral assays reveal no effect on memory in HGPS
animals
To functionally evaluate a possibly signiﬁcant pathology in the
hippocampi of the HGPS animals, we performed behavioral
assays. The novel object recognition (NOR) test revealed no differ-
ence in object memory consolidation between HGPS and wild-
type animals, and both groups had a signiﬁcant preference for
the novel object in the probe trial (Fig. 6A and B). In the short-
protocol of the Barnesmaze test (Fig. 6C–E), we detected changes
by training trails (within group effect) but not by genotype
(between-group effect).
Adult neurogenesis appears unaffected by progerin
expression
The subgranular zone of the hippocampal dentate gyrus is one
area of the brain with postnatal production of neurons (26). To
analyze the effect of progerin on cell proliferation, we stained
hippocampal sections from 20- and 90-week-old HGPS and
wild-type animals and counted the Ki67-positive cells in the
hilus of the dentate gyrus. The result showed no signiﬁcant dif-
ference in the number of proliferating cells between HGPS and
wild-type mice at 20 or 90 weeks of age (Fig. 6F). To determine if
the expression of progerin had an effect on adult neurogenesis,
we performed repeated bromodeoxyuridine (BrdU) labeling of
dividing cells for ﬁve consecutive days, in 54- or 57-week-old
HGPS and wild-type mice (n = 4 per sample group). Following a
chase period of 16 days, animals were sacriﬁced and hippocampi
from each animal were collected and sectioned. Eight microtome
sections, collected every tenth section, from each hippocampus
were double-labeled with BrdU and doublecortin (DCX, a marker
for immature neurons) or BrdU and NeuN (a marker for mature
neurons). Counting of double-positive cells for BrdU and DCX
showed no signiﬁcant difference (P = 0.28), indicating that the
fraction of newly formed and immature neurons was similar be-
tween HGPS and wild-type animals (Fig. 6G). To assess the differ-
ence in regenerative patterns between HGPS and wild-type
animals, the cells positive for DCX or only positive for BrdU
were also counted. Although the fraction of cells that were DCX
positive but BrdU negative were larger than expected, the results
did not reveal a signiﬁcant difference between wild-type and
HGPS animals (P = 0.94) (Fig. 6H). Additionally, the fraction of
cells that were only positive for BrdU did not show a signiﬁcant
difference between the HGPS and wild-type animals (P = 0.37),
which suggested that other proliferating cells in the hippocam-
pus were unaffected (Fig. 6H). Counting of double-positive cells
for BrdU and NeuN showed no signiﬁcant differences between
the HGPS and wild-type animals (P = 0.65; Fig. 6I), suggesting
that the fraction of neurons that have reachedmaturitywas simi-
lar in both populations.
Ex vivomagnetic resonance imaging reveals no effect on
hippocampal volume in HGPS animals
Ex vivo magnetic resonance imaging (MRI) was performed to as-
sess changes in hippocampal volume indicative of hippocampal
atrophy (27,28). Ninety-ﬁve- or 109-week-old HGPS andwild-type
mice (n = 3 per sample group) were examined using a 9.4 T Varian
MRI system. Hippocampal volumes were outlined manually
using the software ITK-SNAP (Fig. 6J). There was no signiﬁcant
difference (P = 0.77) in hippocampal volume between the HGPS
and wild-type sample groups (Fig. 6K).
Discussion
Although lamin A is expressed in terminally differentiated cells,
the phenotype of HGPS is restricted to certain tissues, usually of
mesenchymal origin. Several suggestions have been proposed to
explain the apparent lack of phenotype in the brain (22,23). How-
ever, it is important to add that, to our knowledge, no results of
systematic neuropathologic evaluations of brain samples from
HGPS subjects have been published. In this study, we analyzed
the effects of long-term neural expression of the common pro-
geroid lamin A mutation, LMNA c.1824C>T; p.G608G, to test the
hypothesis that neuropathological changes would likely occur
in children with HGPS if they were to live longer. The results pre-
sented in this work indicate that the detrimental effects of pro-
gerin expression were less than anticipated in the brain, even
after 90 weeks of transgenic expression. Careful pathological
examination of HGPS brain tissue did not indicate any signiﬁcant
changes, except for neuronal nuclear distortions, compared with
wild-type mice of the same age.
Accumulation of progerin was previously suggested to con-
tribute to the phenotype development in HGPS (5,10). In this
study, we analyzed the accumulation of transgenic lamin A/pro-
gerin and progerin using immunoﬂuorescence with antibodies
speciﬁc to human lamin A/progerin or progerin in the brain,
bone and heart. Our results suggested that progerin accumulates
in neuronal cells of thehippocampus and the frontal cortex of the
brain, but not in cardiomyocytes of the atrium and ventricle of
the heart. However, accumulation of lamin A/progerin was seen
in ventricles and atria. This discrepancy may have been due to
sensitivity differences in the antibodies. In bone tissue, there
was a decrease in the number of transgene-positive cells. To
rule out the possibility of increased loss of osteocytes in HGPS an-
imals, as previously reported in HGPS (11), the number of empty
osteocyte lacunawere counted. However, no evidence suggestive
of early loss of osteocytes was observed. Difference in the accu-
mulation of progerin between different types of tissues may be
dependent on the initial level of progerin expression, which var-
ied between different tissue types, or due to the detection range
for the progerin antibody being limited.
Ultrastructural analysis of neurons, adipocytes, osteoblasts
and osteocytes from HGPS mice showed that a signiﬁcant frac-
tion of the neurons and adipocytes showed increased nuclear
distortion compared with the wild-type animals. It is important
to note that the fraction of neuronal cells of the hippocampus
that showed expression of transgenic lamin A and progerin was
91% after 90 weeks of expression. This is in contrast to results
from quantiﬁcation of the transgenic expression of human
lamin A and progerin in the bone after 90 weeks of transgenic ex-
pression, in which only a very small fraction of osteocytes, <1%,
expressed the transgene. Unfortunately, wewere unable to quan-
tify adipocytes with transgenic expression using immunoﬂuor-
escence or immunohistochemistry. Analysis of the skin with
antibodies to human lamin A and progerin only identiﬁed very
scattered cells with transgenic expression in the dermis, the
bulb region of the hair follicle and the hypodermis. The loss of
subcutaneous fat in HGPS animals suggests that the proportion
of transgene-positive adipocytes may be higher than identiﬁed,
or that there may be a systemic response that causes this loss.
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Recently, Karakasilioti et al. (29) reported amousemodel for xero-
derma pigmentosum with a DNA repair defect that resulted in a
range of premature aging symptoms, including fat depletion.
They showed that DNA damage triggered a chronic autoinﬂam-
matory reaction, which in turn caused fat depletion in their
mouse model (29). Taking this into consideration, further ana-
lysis is needed to determine the origin of the fat depletion seen
in our mouse model.
While post-mitotic cells have lost their ability to proliferate,
mitotic cells are capable of proliferation (30). Both the brain and
adipose tissue are mainly composed of post-mitotic cells. How-
ever, recent evidence suggests that limited repairand regeneration
also occurwithin these tissues. In the hippocampus of the brain, it
was shown that one-third of neurons are subject to change with
an annual turnover of 1.75% of neurons within the renewing frac-
tion (31). Approximately 10% of adipocytes are renewed annually
(32). One explanation for the lack of neurodegeneration in HGPS
may be that post-mitotic cells are less sensitive to structural de-
fects, and the effect onadipocytesmight be the result of a systemic
response induced by chronic autoinﬂammatory reaction (29,33).
Our data show that the capacity of the ubiquitin/proteasome
system in progerin-expressing cells is sufﬁcient to safeguard deg-
radation of ubiquitin-dependent substrate. This is in contrast to
an earlier report, which indicated that the activity of the prote-
asome is reduced in ﬁbroblasts of HGPS patients (17). However,
it is noteworthy that cells contain excessive proteasome activity
because under normal conditions, the activity of the dominant
chymotrypsin-like activity has to be inhibited >80% to induce ac-
cumulation of ubiquitylated substrate (34). Even more striking is
that the caspase-like activity can be completely inhibited by se-
lective inhibitors without affecting the functionality of the prote-
asome in ubiquitin-dependent proteasomal degradation (35).
A recent publication suggested that the expression of lamin A
in the brain is regulated bymiR-9 and that this miRNAmaintains
Figure 6. Functional analysis of hippocampus and neurogenesis in HGPS animals. (A and B) Objectmemory consolidation. (A) Pre-trial with two identical objects (left and
right). Fraction of the time spent at each object on the ordinate, while object position is displayed on the abscissa. Key to genotype can be found in A. (B) Probe trial with
familiar and novel objects. Both groups showa preference for the novel object (paired t-test; P < 0.001). Themean and SEM have been indicated. (C–E) Barnesmaze test on
spatial memory and learning. (C) The escape latency decreases across trials (T1–T5) in parallel with an improvement in primary latency (ﬁrst encounter with correct hole)
shown in (D) and the decrease in total number of holes searched in each trial (E). The improvement in escape latency across trials was evident within animals (F = 6.3;
P < 0.001) but not between animal groups (F = 4.0; P = 0.07); thus, the slightly better performance of the HGPS line did not reach statistical signiﬁcance. (F) No difference
was detected between HGPS and wild-type animals at both 20 and 90 weeks of hippocampal cell proliferation. (G–I) Adult neurogenesis in HGPS and wild-type
animals measured by double labeling with BrdU/DCX (G and H), BrdU/NeuN (I). (J) Hippocampal volumes were manually outlined using the ITK-SNAP software. A
representative MRI image illustrating segmentation of the hippocampus from HGPS mice is outlined in the ﬁgure. (K) No signiﬁcant difference, indicative of
hippocampal atrophy, was seen between HGPS and wild-type mice. The mean and SEM have been indicated.
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the expression of laminA and progerin in aHGPSmousemodel at
undetectable levels (22). In our model system, we saw expression
of the HGPS mutation in the hippocampus, frontal cortex and
cerebellum. However, we did not identify any signiﬁcant changes
in the miRNA levels in HGPS animals compared with the wild-
type animals in any regions of the brain. The reason for this result
could be because during the construction of the target transgenic
mouse, the 3′ untranslated region (UTR) included in the LMNA
gene was very short (36), and therefore our model may be less
sensitive to miRNA regulation.
A previous study that usedwhole-genome expression analysis
in cells from HGPS patients identiﬁed >300 genes that showed a
signiﬁcant difference of at least 2-fold (25). Whole-genome exon
array analysis of neuronal cells from the hippocampus in our
HGPSmice andwild-type controls showed that only ﬁve genes de-
monstrated a signiﬁcant 2-fold change. This is surprising because
one might imagine that severe nuclear distortion would have a
more signiﬁcant effect on the gene expression. This is in agree-
ment with a previous study that reported nuclear distortion of
keratinocytes without effects on the skin in a transgenic mouse
model. However, this study assessed expressed progerin fused
with a ﬂag epitope tag and did not analyze changes in gene
expression (37). The behavioral tests showed that object memory
consolidation was unaffected by the expression of progerin
(Fig. 6A and B) and that both genotypes behaved similar to aged-
matched C57BL/6J (38). The preserved object memory consolida-
tion process is relevant for the results in Barnes maze because
the spatial navigation strategy to ﬁnd the escape hole depends
on recollection of the static object queues present around the
arena (39). The results recorded in the Barnes maze, used here to
assess spatialmemoryand learning, detectedno signiﬁcantdiffer-
ence between genotype. Taken together, our results support the
hypothesis that neuronal cells are less sensitive to progerin ex-
pression, regardless of its sustained expression in adulthood.
Experimental Procedures
Transgenic mice
Animalswere housed in a 12-hour light/dark cycle at 20–22°C and
55–65% air humidity in a pathogen-free animal facility at the Kar-
olinska University Hospital. The mice were fed irradiated mouse
pellets RM3 (Scanbur BKAB) andwaterad libitum. NSE-tTA (line A)
(40) promoter mice were maintained on a CD1 background and
were intercrossed with transgenic tetop-LAG608G mice, line VF1-
07, generated and maintained on FVB/NCrl (36). HGPS mice re-
ferred to throughout the paper correspond to tetop-LAG608G+;
NSE-tTA+ mice, and tetop-LAG608G−; NSE-tTA− mice are referred
to as wild-type. Tetop-LAG608G+; NSE-tTA− mice were also in-
cluded and are referred to as single transgenic animals. Ten 20-
week-old wild-type animals (n = 7 females; n = 3 males) and 10
HGPS animals (n = 7 females; n = 3 males) were used for weight
analysis. Likewise, eight 90-week-old animals (n = 4 for each
group, all male) were used for weight analysis and other experi-
ments, as stated below. NSE-tTA+ mice were intercrossed with
transgenic tetop-LAG608Gmice, of the line VF1-07, that was gener-
ated andmaintained on C57BL/6J. Animal studies were approved
by the Stockholm South Ethical Review board, Dnr S107-09, S12-
11 and S101-12. Behavioral studies were approved by the Stock-
holm North Ethical Review board, Dnr N206/2012 and N84/2014.
Tissue collection and preparation
For RNAandprotein extractions, animalswere sacriﬁced by cervical
dislocation without anesthesia. The whole brain was rapidly
removed from the skull and immediately frozen in liquid nitrogen
or placed into an ice-cold 0.9% saline solution. The brain (placed
in ice-cold saline) was then dissected on a cold plate into three re-
gions: cerebellum, cortex and hippocampus under the microscope.
The dissection plate was placed on dry ice to keep the tissue cold.
Other tissues, such as bone (femur), skin and heart, were collected
as quickly as possible. The bone marrow was ﬂushed out from the
femur with phosphate-buffered saline (PBS). Dissected tissue sam-
ples of individual structures were immediately frozen in liquid ni-
trogen and stored separately at −80°C until use.
For histological staining, immunoﬂuorescence and immuno-
histochemistry, animals were anesthetized with ketamine
(90 mg/kg, i.p.) and xylazine (7.5 mg/kg i.p.) before undergoing
transcardial perfusion. Each animal was ﬁrst perfused with PBS
to rinse out blood, followed by 4% paraformaldehyde (PFA) in
PBS, pH7.4. The perfusion solutionwasdeliveredat aconstant vol-
ume of 10 ml/min using an automatic pump. After harvesting the
brain, it was immersed in 4% PFA overnight. The carcass was also
ﬁxed overnight in 4% PFA. On the following day, the brain and dor-
sal skin tissues were sent for dehydration processing and parafﬁn
embedding. The brainwas divided in the sagittal plane, and femur
bones were decalciﬁed for 3 weeks using 12.5% ethylenediamine-
tetraacetic acid (EDTA) (pH 7.0) prior to parafﬁn embedding.
RNA analysis
Twenty-week HGPS and wild-type littermates (n = 3 for each
group; onemale and two females)were used for all RNA analyses.
C57BL/6J animals that were never intercrossed with transgenic
mice are referred to as ‘pure’ wild-type, and 3-, 87- and 126-
week animals [n = 4 for 3-week (one male; three females) and
87-week (four females); n = 3 for 126-week (three males)] were
used. Snap-frozen tissues were homogenized in ice-cold TRIzol
reagent (Invitrogen), and total RNA was extracted according to
themanufacturer’s protocol. After resuspension of RNA in nucle-
ase-freewater (Gibco), the samplesweremeasured and evaluated
for concentration and purity (260 nm/280 nm ratio) using a Bio-
Photometer (Eppendorf ), in which values between 1.7 and 2.0
for 260/280 nm ratio were considered optimal. Twenty micro-
grams of each RNA sample from skin, heart, kidney and lung
was further puriﬁedwithDNase I (RQ1 RNase-free DNase, Prome-
ga) andRNeasymini columns (Qiagen) according to themanufac-
turer’s instructions. Samples were stored at −80°C until use.
cDNA was synthesized from 1 μg of total RNA using random
hexamers and SuperScript II reverse transcriptase (Invitrogen).
To examine the presence of our transgene, RT-PCR for human
lamin A and progerin was performed as previously described
(36). β-actin was used as a control. Levels of human lamin A
and progerin transcript were measured by quantitative RT-PCR
(qRT-PCR) as previously described (41). Brieﬂy, qRT-PCR reactions
were prepared in triplicate for each sample with Power SYBR®
Green PCR Master Mix (Life Technologies) and performed on a
7500 Fast Real-Time PCR system (Applied Biosystems). Transcript
levels were determined by the comparative cycle threshold
method and normalized to levels of β-actin. Speciﬁc primers for
human lamin A and progerin were used for both RT-PCR and
qRT-PCR. Primer sequences for the Lmnb1 gene have previously
been published (22), and sequences for progerin, lamin A, and
β-actin can be provided upon request.
Western blotting
Twenty-week HGPS (n = 3; two females and one male) and wild-
type or single-transgenic littermates controls (n = 3; two females
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and one male) were used for western blotting. Tissues were
homogenized in 5% radio-immunoprecipitation assay buffer
containing 8 M Urea and proteinase inhibitor (Roche). Western
blots were performed as previously described (36). Brieﬂy, a
mouse monoclonal anti-human lamin A/C antibody (mab3211,
Chemicon) that does not cross-react with mouse lamin A/C pro-
tein was used to analyze transgenic expression at the protein
level. To quantify the transgenic expression relative to wild-
type mouse lamin A/C, we used an antibody raised against the
N-terminal end of laminA/C (sc-6215, Santa Cruz Biotechnology),
which recognizes lamin A/C of both human and mouse origin.
Secondary antibodies usedwere HRP-conjugated rabbit anti-goat
(305-035-045, Jackson Immuno Research) and HRP-conjugated
goat anti-mouse (115-036-062 and 115-035-062, Jackson Immuno
Research). Protein extracts from HGPS patient cell line AG03506
were used as a control. The levels of protein expression for the
mouse and human lamin A were normalized against β-actin
(A5441, Sigma). Relative quantiﬁcation using densitometry of
the lamin A to lamin C proteins in brain (n = 3; three males),
liver (n = 3; one female and twomales), kidney (n = 6; two females
and four males) and bone (n = 6; one female and ﬁve males) from
adult wild-type mice was performed according to a previously
described procedure (41). Leakiness expression of the transgene
in the brain was quantiﬁed using the transgene-speciﬁc lamin
A/C antibody (mab3211, Chemicon) on protein extracts of brain
from HGPS and tetop-LAG608G+; NSE-tTA− single transgenic
mice.
Bone measurements
The length and width of femur and tibia bones from 20-week
HGPS and wild-type littermates (n = 3 for each group; one male
and two females) were measured using an electronic digital cali-
per. The bone length was deﬁned as the distance between the
most distal part and the most proximal part of the bone; femur
length was measured between the condyle and the greater tro-
chanter, and tibia length was measured between the malleolus
and the tibial tuberosity. Bone thickness was measured at the
middle of the bone andwas deﬁned as the distance from the pos-
terior to the anterior side of the bone.
Histological staining
Twenty- and 90-week HGPS and wild-type animals (n = 3 of each
group for 20-week; onemale and two females, n = 4 of each group
for 90-week; four males) were used for all histological staining as
well as immunoﬂuorescence and immunohistochemistry. For
heart tissue, 74-week HGPS (n = 3 females; n = 2 males) and
wild-type littermates (n = 1 female; n = 2males) were used instead
of 90-week HGPS. Four-micrometer-thick sections of brain, skin,
bone and heart tissues were cut using amicrotome and collected
on Superfrost glass slides (Thermo Scientiﬁc). Sections were in-
cubated for 30 min at 60°C for adhesion of sections onto glass
slides. These sections were processed for automated H&E and/or
Masson’s trichrome staining according to standard procedures.
Immunoﬂuorescence
Four-micrometer-thick sections of parafﬁn-embedded brain,
skin and heart were cut using a microtome and collected on
Superfrost Plus glass slides (Thermo Scientiﬁc, Waltham, MA,
USA), whichwere then incubated for 30 min at 60°C for adhesion.
Each step was carried out at room temperature unless otherwise
stated. For transgenic lamin A/progerin, progerin and keratin-5
labeling, sections underwent antigen retrieval in a pressure cook-
er, in which the sections were completely immersed in a 0.5 M
EDTA, pH 8 solution. For BrdU, Ki67, NeuN and DCX labeling, sec-
tions underwent a double-antigen retrieval step including incu-
bation in the microwave (700 W for 8 min in 10 m citrate
buffer at pH 8) that was followed by incubation in 2  HCl (37°C
water bath for 30 min). Following antigen retrieval, blocking
was performed using 3% normal goat serum and then a mouse-
to-mouse blocking reagent (Scytek, Logan, UT, USA). Primary
antibodies included anti-human Lamin A/C (1 : 30, mab3211;
Chemicon), anti-progerin (1:100, mAb13A4; Enzo Life Science),
anti-Keratin5 (1:1000, PRB-160P; BioSite, San Diego, CA, USA),
anti-ubiquitin (1:200, U5379; Sigma), anti-BrdU (1:25, 347580; BD
Bioscience), anti-NeuN (1:100, ABN78; Millipore), anti-DCX (1:75,
ab18723; Abcam) and anti-Ki67 (1:100, VP-K452; Vector Laborator-
ies). Primary antibodies were incubated at 4°C overnight. Corre-
sponding secondary antibodies were Alexa 488-conjugated
donkey anti-goat (1:100, A-11055; Life Technologies), Alexa 488-
conjugated goat anti-rabbit (1:100, A-11034, Life Technologies),
Alexa 555-conjugated goat anti-mouse (1:100, A-2122, Life Tech-
nologies) and Fitc-conjugated goat anti-rabbit (1:300, ab6717,
Abcam), which were incubated for 30 min at room temperature.
Sections were counter-stained with DAPI (1:1000; Vector Labora-
tories) for 5 min prior tomounting (Vectashieldmountingmedia,
Vector Laboratories). Imaging was performed on a Nikon A1R,
and an A1+ imaging system (Nikon Corporation, Japan).
Immunohistochemistry
Four-micrometer-thick sections of parafﬁn-embedded tissues,
collected on Superfrost Plus glass slides (Thermo Scientiﬁc,
Waltham, MA, USA), were analyzed for cleaved caspase-3 (for
brain and heart tissues) GFAP and aberrant Tau (for brain tissue).
Antigen retrieval for cleaved caspase-3 labeling required an incu-
bation of sections in 10 m citrate buffer, pH 6, at 95°C in water
bath for 30 min, and for the aberrant Tau labeling, it required
an incubation in formic acid at room temperature for 30 min. Fol-
lowing antigen retrieval, sections were blocked with 3% normal
goat serum prior to anti-cleaved Caspase 3 (1:200, cab 9664, cell
signaling), anti-GFAP (1:25000, MAB360, Millipore) and aberrant
Tau (1:100, MC-1, (42)) primary antibody incubation at 4°C. The
following day, biotinylated goat anti-rabbit secondary antibody
(1:200, 65-6140, Zymed) or goat anti-mouse secondary antibody
(1:300, 62-6540, Zymed) was applied for 30 min at room tempera-
ture, followed by the label antibody (ABC Elite; Vector Laborator-
ies, Burlingame, CA, USA) for 30 min. DAB chromagen (Dako
Cytomation, Carpinteria, CA, USA) was applied for 3 min, fol-
lowed by rinsing with distilled water. Sections were then coun-
ter-stained with Mayers hematoxylin (Histolab), then mounted
with mounting medium for light microscopy (Pertex, Histolab).
For bone tissues, 4-μm-thick sections of parafﬁn-embedded
femur, collected on Superfrost Plus glass slides (Thermo Scientiﬁc,
Waltham, MA, USA), were labeled for transgenic lamin A/progerin
(1:3000,mab3211, Chemicon). All procedureswere identical to cas-
pase-3 labeling except that antigen retrieval was performed at
97.5°C and DAB was exposed for 2 min. A biotinylated goat anti-
mouse secondary antibody (1:400, 62-6540, Zymed) was used.
Quantiﬁcation of immunoﬂuorescent staining
Using confocal microscopy, immunoﬂuorescent images were
taken from 20- and 90-week HGPS brain tissues (n = 3 (two fe-
males, one male) for 20-week HGPS, n = 4 (four males) for 90-
week HGPS), and from 20- and 74-week HGPS heart tissues
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[n = 3 (2 females, 1 male) for each age group] that were labeled for
transgenic lamin A/progerin or progerin. From these images, 400
DAPI-positive cells were counted, and among these, 400 DAPI-
positive cells, transgenic lamin A/progerin- or progerin-positive
cells were counted to calculate the frequency of cells expressing
transgenic lamin A/progerin or progerin. Quantiﬁcation was con-
ducted in two different brain regions: frontal cortex and CA1 re-
gion of hippocampus, and in the ventricle and atrium of the
heart. The number of transgenic lamin A/progerin- or progerin-
positive cells was too low in the cerebellum for quantiﬁcation,
and the area was excluded.
Quantiﬁcation of immunohistochemical staining in bone
Quantiﬁcation of cells positive for transgenic lamin A/progerin
expression was conducted in the diaphyseal cortical bone region
of femur from 20- (n = 4; three females and one male) and 90-
week (n = 4; four males) HGPS animals using a Nikon Eclipse
E1000 microscope. A minimum of 2000 osteocytes were counted
for each animal, and then the number of transgenic lamin A/pro-
gerin-positive cells were counted to calculate the frequency of
osteocytes expressing transgenic lamin A/progerin. We also
counted osteocytes in 3-week femurs from Tetop-LAG608G+; Sp7-
tTA+, F1-line VF1-07, expressing the HGPS mutation in bone tis-
sue (n = 3; three females), andwild-type littermate controls (n = 3;
2 females and 1 male) (11).
Quantiﬁcation of empty osteocyte lacuna
Quantiﬁcation of the presence of empty osteocyte lacuna was
conducted in H&E-stained sections of femur from 20-week
HGPS (n = 3; three females) and wild-type animals (n = 3; one fe-
male and two males) and 90-week HGPS and wild-type male an-
imals (n = 3 per genotype). Five hundred osteocyte lacuna in the
diaphyseal cortical bone region were counted in each animal.
Transmission electron microscopy
Seventy-week animals [n = 2 (onemale and one female) for HGPS;
n = 1 (female) forwild-type]were sacriﬁcedby cervical dislocation,
and the hippocampus, femur and abdominal white fat were dis-
sected. These tissues were ﬁxed in 2% glutaraldehyde + 1% PFA
in 0.1  phosphate buffer, pH 7.4 at room temperature for
30 min and stored at 4°C. Specimens were rinsed in 0.1  phos-
phate buffer, pH 7.4 and post ﬁxed in 2% osmium tetroxide 0.1
phosphate buffer, pH 7.4 at 4°C for 2 h, dehydrated in ethanol fol-
lowed by acetone, and embedded in LX-112 (Ladd, Burlington,
Vermont, USA). Semi-thin sections were cut and stained with
toluidine blueO and used for lightmicroscopic analysis. Ultrathin
sections (∼40–50 nm) were cut by a Leica EM UC 6 (Leica, Wien,
Austria) and contrasted with uranyl acetate followed by lead cit-
rate andexaminedusing aTecnai 12 Spirit BioTWIN transmission
electron microscope (FEI Company, Eindhoven, The Netherlands)
at 100 kV. Digital images were randomly takenwith a Veleta cam-
era (Olympus Soft Imaging Solutions, GmbH, Münster, Germany).
A total of 130 hippocampal neurons, 50 osteoblasts, 50 osteocytes
and 50 adipocyteswere assessed for nuclear shape. To be counted
as a misshapen, the nucleus had to present with lobulations and
folds that altered the normal round shape of the nucleus.
Ubiquitin-dependent proteasomal degradation reporter
assay
Human melanoma cell MelJuSo line stably expressing UbG76V-
GFP, which has been previously described (43), was grown in
DMEM GlutaMAX™medium (Life Technologies) complemented
with 10% FCS at 37°C under 5% CO2. To generate the pHcRed1-
C1_mycLAΔ150 expression vector, the pET3-LAΔ150 (5) was
digested with BamHI and XbaI, and the mycLAΔ150 insert frag-
ment was gel-puriﬁed and ligated to a pHcRed1-C1 vector (BD
Biosciences Clontech), previously digested with BamHI and
XbaI. Additional vectors were generated from the pHcRed1-
C1_mycLAΔ150 vector. The vector was ﬁrst digested with XbaI,
then ﬁlled in with T4 DNA polymerase and gel-puriﬁed to remove
the LAΔ150 insert. The previously published pIRES2-eGFP-tetop-
LAwt and pIRES2-eGFP-tetop-LAG608G vectors (LA-77 and LA-75, re-
spectively) (36) were digested with BamHI before being ﬁlled in
with T4 DNA polymerase and digested with AscI to release the
LAminigenes for gel puriﬁcation. The LAminigenes were then li-
gated to the gel-puriﬁed pHcRed1-C1_myc vector fragment to gen-
erate the pHcRed1-C1_LA-75, and pHcRed1-C1_LA-77 vectors.
Transient transfection with cellular expression vectors was per-
formed using Lipofectamine® 2000 transfection reagent (Life
Technologies) according to the manufacturer’s protocol. MelJuSo
UbG76V-GFP stable human melanoma cells were grown on 18mm
coverslips in six-well plates for 24 h after transfection. MG132 was
added 5 hbeforeﬁxation in a 10 µmconcentration. Cellswere then
ﬁxed for 20 min in PBS with 4% PFA and mounted with 10%
Mowiol®; 2.5% 1,4-diazabicyclo[2.2.2]octane, 25% glycerol in
0.1 m Tris, pH 8.5. Images were acquired on a Zeiss LSM510
META confocal laser scanning microscope with a Zeiss Plan Apo-
chromat 63x/1.40 oil DIC objective (Carl Zeiss, Jena, Germany) op-
erated by LSM5 software. The images were processed using the
Zeiss LSM Image Browser software.
MicroRNA analysis
Twenty-week HGPS and wild-type littermates (n = 3 for each
group; one male and two females) were used for miRNA-9,
miRNA-124 and miRNA-129 analyses. Three-, 87- and 126-week
pure C57BL/6J wild-type animals [n = 4 for 3- (one male; three fe-
males) and 87-week (females); n = 3 for 126-week (males)] were
used for miRNA-23a analysis. Total RNA was isolated from
snap-frozen mouse brain tissues using a mirVANAmiRNA isola-
tion kit (Ambion), and RNA samples were quantiﬁed and evalu-
ated for purity (260/280 nm ratio) using a spectrophotometer
(BioPhotometer, Eppendorf ). miRNA detection was performed
using TaqMan microRNA assays (Applied Biosystems) with a
no-UNG no-Amperase master mix (Applied Biosystems) accord-
ing to manufacturer’s instruction. Brieﬂy, 10 ng of total RNA
was reverse-transcribed using the TaqMan miRNA reverse tran-
scription kit (Applied Biosystems) and PCR ampliﬁed using an
Applied Biosystems 7500 Real-Time PCR system. As an internal
control, miRNA expression was normalized against snoRNA202.
All protocols were performed according to the manufacturer’s
instruction.
Statistical analysis
Statistical analyses were performed using one- and two-way
ANOVAs, unpaired Student’s t-test and a Chi-squared for life
span. A two-tailed P-value of 0.05–0.01was considered signiﬁcant
(*), a P-value of 0.01–0.001 is indicated as ** and a P-value smaller
than 0.001 is indicated as ***, unless otherwise indicated.
Exon array analysis
Sixty-three-week-old HGPS (n = 3; females) and wild-type ani-
mals (n = 3; one female and twomales) were sacriﬁced by cervical
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dislocation before the hippocampus was dissected and snap-fro-
zen in liquid nitrogen as described in the previous section. Total
RNAwas extracted using the mirVANAmiRNA isolation kit (Am-
bion), which was then quantiﬁed using a spectrophotometer
(BioPhotometer, Eppendorf ), followed by a quality check with
the Agilent Tapestation 2200. The criteria for high-quality RNA
were an RNA Integrity Number (RIN) above 8.0 and ribosomal
ratio (28S/18S) above 1.5. One hundred ﬁfty nanograms of RNA
from each animal were used in preparation for Affymetrix
whole transcriptome (WT) microarray analysis using an Ambion
WT Expression Kit (Affymetrix, Santa Clara, CA, USA). Samples
were then hybridized to mouse Affymetrix GeneChip Sense Tar-
get (ST) Arrays and incubated in a rotating hybridization 640 oven
(Affymetrix) at 45°C for 16 h at 60 rpm. Following hybridization,
the arrays were washed and stained on an GeneChip® Fluidics
450 workstation (Affymetrix, Santa Clara, USA) using the FS450_
0001 and FS450_0007 ﬂuidics script. The arrays were scanned
using the 3000 7G Affymetrix GeneChip Scanner (Affymetrix,
Santa Clara, CA, USA). Labeling and hybridization of all exon
arrays were performed at the Bioinformatics and Expression
Analysis (BEA) core facility (Karolinska Institutet, Sweden). Affy-
metrix CEL ﬁles with exon array raw datawere imported into Par-
tek Genomic Suite software (Partek Inc., St. Louis, MO, USA) and
ﬁltered to include only those probe sets in the ‘main’meta-probe
list, which represents 16,572 RefSeq genes and full-length
GenBank mRNAs. The main data include target-sequence, per-
fect-match, unique probe sets. Robust multi-array average is
not an algorithm from Affymetrix but has been implemented
into the Affymetrix Expression Console (EC). Robust multi-array
average includemethods for summarization, background correc-
tion and normalization. For robust multi-array average (RMA)
references, see http://bmbolstad.com/misc/ComputeRMAFAQ/
ComputeRMAFAQ.html, last accessed on 30 October 2014. Nor-
malized probe signals were converted into a log 2 scale, which
was a default setting in the RMAmethod. Annotations were pro-
vided by Affymetrix (NetAffx build 32). Sample data quality was
assessed by the EC report, the quality control steps in Partek
and visual inspection of the images from scanning. All arrays
met all quality parameters established by Affymetrix, and no
outliers were detected. Detection of differentially expressed
genes was performed by following the pre-deﬁned exon work
ﬂow menu in Partek. Exons were summarized into genes and
analysis of variance was performed. A list of changed genes
was chosen on the basis of a 2-fold increase or decrease in the ex-
pression level in HGPS hippocampal samples compared with the
wild-type, together with an FDR P-value of <0.05.
Behavioral studies
Eight HGPS and eight wild-type male littermate mice between 55
and 60 weeks old were subjected to behavioral analysis of object
and spatial memory. After arrival at the behavioral suite, the an-
imals were allowed to acclimatize for 1week. In the secondweek,
object (reference) memory was examined by means of the
NOR test, as described in detail elsewhere (44). After a pause of
1 week, the same animals were tested in the Barnes maze (39)
using an arena measuring 124 cm in diameter with 36 holes
each with a width of 4.5 cm. In this test, we used a shortened
protocol developed by Attar et al. (45) with ﬁve training trials
over 2 days followed by the probe trial on the third day. This
protocol emphasizes the early learning phase and has been
shown to bemore sensitivewith respect to discrete spatial learn-
ing difﬁculties/memory consolidation than the standard protocol
with 15 training trials (45). The only aversive stimulus used was
light (indirect light providing an illumination of the arena of
600 Lux from above and 400 Lux from below). All tests were re-
corded with a high-resolution video camera at 15 frames per
second and fed into a computer where the records were analyzed
with the Ethovision XT10 software (Noldus, The Netherlands).
Software settings were not changed between groups and all ana-
lyses were executed at least twice. A paired Student’s t-test was
used to assess results from theNOR testwhile repeatedmeasures
used ANOVA (with genotype as in-between factor and trials as
within-subject variable). In case of signiﬁcance, a post-hoc Bonfer-
roni analysis was performed. Statistical signiﬁcance was set to
P < 0.05. For all analyses, the Statistical V6 software was used.
Adult neurogenesis
BrdU labeling of dividing cells in the dentate gyrus of the hippo-
campuswas used tomonitor neurogenesis (26) in HGPS andwild-
type female mice. Fifty-four- or 57-week-old bitransgenic (n = 4)
and wild-type (n = 4) mice were injected intraperitoneally every
24 h during ﬁve consecutive days with BrdU (50 mg/kg body-
weight). The mice were sacriﬁced 16 days after the ﬁrst day of in-
jection. The whole hippocampus was cut into 4-μm-thick
sections. The sections were dried at 60°C for 1 h and processed
for double-labeling experiments with BrdU/DCX and BrdU/
NeuN. Every tenth section was stained, and positive neuronal
cells, for a total of eight sections/animal, were counted.
Ex vivoMRI
Whole-brain samples from HGPS (n = 3; one female and two
males) and wild-type (n = 3; one female and two males) mice
95- or 109-week-old were analyzed using MRI. MRI data were ac-
quired using 9.4 T scanner (Agilent Technologies, Santa Clara,
CA, USA) with a millipede coil of 30 mm inner diameter. PFA
ﬁxed brains were positioned in a syringe ﬁlled with Fomblin YL
VAC 06/6 (Solvay Specialty Polymers, Italy), to provide a cylindric-
al shape of homogenous magnetic susceptibility. A 3D multi-
echo sequence was acquired where 10 spin echos were acquired
with 6.37 ms separationwith a TR time of 800 ms. Thematrix size
was 512 × 256 × 256 covering a ﬁeld of view of 51.2 × 25.6 × 25.6
mm3. A single exponential decay was ﬁtted to each pixel and
an image corresponding to a TE time of 25 ms was calculated
from the T2 and initial intensity. The hippocampi weremanually
segmented using the software ITK-SNAP version 3.2.0 (46).
Supplementary Material
Supplementary Material is available at HMG online.
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